2016-08-08T17:22:06-05:00 2016-03-31 910189318 Moss Adams LLP 805 SW Broadway Ste 1200 Portland OR 97205 990 2015-04-01 954002032 Alfred E Mann Foundation for Scientific Research ALFR 6617026700 25134 Rye Canyon Loop Santa Clarita CA 91355 DAVID HANKIN CEO 6617026700 2016-08-03 1 Wendy Campos P00448102 5032421447 2016-08-02 2015 2016-12-15 16:53:06Z DAVID HANKIN 25134 Rye Canyon Loop Santa Clarita CA 91355 118132469 0 X www.aemf.org X 1985 CA CONDUCT MEDICAL AND SCIENTIFIC RESEARCH 4 4 89 9 385640 90247 101479 1124238 1859751 926616 5583714 2867141 49760 -377460 7594704 4540535 19000 7000 0 0 10585260 10867512 0 0 65643 7298385 6378698 17902645 17253210 -10307941 -12712675 108633540 82113434 15219334 8156995 93414206 73956439 X THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH IS A MEDICAL RESEARCH ORGANIZATION DEDICATED TO DEVELOPING AND COMMERCIALIZING INNOVATIVE SOLUTIONS FOR SIGNIFICANT UNMET MEDICAL CONDITIONS. 0 0 5235853 7000 426616 IMPLANTABLE MYOELECTRIC SENSOR (IMES I + CLINICAL):INITIALLY, THE "IMES" PROJECT WAS A CONSORTIUM PROJECT WITH THE FOLLOWING PARTNERS: NORTHWESTERN UNIVERSITY, THE ILLINOIS INSTITUTE OF TECHNOLOGY, AND SIGENICS (A CLOSELY HELD ENGINEERING COMPANY). THE INITIAL FUNDING FOR THE IMES PROGRAM WAS COMING FROM THE NATIONAL INSTITUTES FOR BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB) AND THE NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (NICHD), AS WELL AS, THE DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA). IN 2008, AMF ASSUMED CONTROL AND RESPONSIBILITY FOR THE ENTIRE PROJECT, PERFORMING MISSION CRITICAL ENGINEERING TASKS AND PREPARING FOR AND CONDUCTING A CLINICAL TRIAL. THE IMES SYSTEM IMPLANTED IN THE RESIDUAL LIMB OF A LIMB AMPUTEE WOULD TRANSMIT MUSCLE SIGNALS TO THE WEARABLE PROSTHESIS TO PERMIT CONTROL OF THE PROSTHESIS IN A MORE NATURAL AND INTUITIVE MANNER. STATUS:AMF HAS QUALIFIED THE FIRST GENERATION IMES SYSTEM FOR A CLINICAL TRIAL WITH UPPER LIMB AMPUTEES. A CLINICAL TRIAL PROTOCOL WAS DEVELOPED AND FDA APPROVAL WAS OBTAINED. THREE PATIENTS HAVE BEEN IMPLANTED AT WALTER REED NATIONAL MILITARY MEDICAL CENTER ("WALTER REED") AND HAVE REPORTED THAT THE NEW EQUIPMENT MADE AVAILABLE TO THEM DURING THE STUDY HAS IMPROVED THEIR QUALITY OF LIFE. AMF SUPPORTS THIS CLINICAL TRIAL DIRECTLY WITH FREQUENT ON-SITE VISITS BY AMF PERSONNEL, WHO WORK IN CONJUNCTION WITH PHYSICIANS AND OTHER CAREGIVERS AT WALTER REED. DURING 2015 AMF ALSO CONTINUED SUPPORTING A COLLABORATION WITH OSSUR, A MAKER OF LOWER-LIMB PROSTHETICS AND OTHER ORTHOTIC DEVICES, WHERE TWO LOWER LIMB AMPUTEE/PATIENTS WERE IMPLANTED WITH IMES DEVICES. ADDITIONALLY, AMF ENTERED INTO A COLLABORATION AGREEMENT WITH OTTOBOCK, THE WORLD'S LARGEST MAKER OF PROSTHETIC DEVICES (BOTH UPPER AND LOWER LIMB), TO EVALUATE IMES DEVICES IN CONNECTION WITH A TRANSHUMERAL (UPPER LIMB) AMPUTEE, WHERE THREE PATIENTS WERE IMPLANTED WITH IMES. THE OSSUR STUDY IS BEING CONDUCTED IN ICELAND, AND THE OTTOBOCK STUDY IS BEING CONDUCTED IN AUSTRIA AT EUROPE'S LARGEST HOSPITAL, VIENNA GENERAL HOSPITAL, UNDER THE AUSPICES OF DR. OSKAR ASZMANN OF THE CHRISTIAN DOPPLER LABORATORY FOR RESTORATION OF EXTREMITY FUNCTION, MEDICAL UNIVERSITY OF VIENNA. THE TWO PATIENTS IN ICELAND AND THE THREE PATIENTS IN AUSTRIA ARE SUCCESSFULLY UTILIZING THEIR DEVICES PER THE CLINICAL TRIAL. 4661350 0 500000 IMPLANTABLE MYOELECTRIC SENSOR II (INFINITY):THE INITIAL COLLABORATION WAS RE-VITALIZED TO COMMENCE RESEARCH AND DEVELOPMENT WORK ON A SECOND GENERATION OF IMES, (PARTIALLY SUPPORTED BY A GRANT FROM THE NATIONAL INSTITUTES OF HEALTH) WHICH WILL CONTAIN ADVANCED FEATURES TO IMPROVE MEDICAL OUTCOMES AT NO ADDITIONAL COST TO THE PATIENT OR HEALTHCARE SYSTEM. INITIAL DESIGN IS COMPLETE WITH MAJOR FOCUS BEING ON THE DEVELOPMENT OF A CUSTOM INTEGRATED CIRCUIT.STATUS: THE FINAL DESIGN OF THE CUSTOM INTEGRATED CIRCUIT IS COMPLETE AND THE DESIGN HAS BEEN TESTED AND VERIFIED. PERIPHERAL DEVICES THAT INCLUDE A TELEMETRY CONTROLLER MODULE THAT RELAYS MUSCLE SIGNALS TO THE PROSTHETIC, AND A CLINICIAN PROGRAMMER ARE UNDERGOING FINAL DESIGN REVIEW. PRODUCTION TEST SYSTEMS ARE BEING VALIDATED TO PREPARE FOR FINAL SYSTEM VERIFICATION AND VALIDATION. PRODUCT QUALIFICATION IS PLANNED FOR CALENDAR YEAR 2016. 3334293 0 23399 ADVANCED TECHNOLOGY PROJECTS (NEW PROJECTS): THE TEAM IS COMPRISED OF RESEARCH SCIENTISTS, ENGINEERS, LEGAL AND INTELLECTUAL PROPERTY EXPERTS, BUSINESS STRATEGISTS AND ANALYSTS WHO MONITOR AND EVALUATE NEW TECHNOLOGIES AND NEW PROJECT IDEAS AND CONCEPTS BEFORE THEY ARE ELEVATED TO THE STATUS OF FULL-FLEDGED DEVELOPMENT PROGRAMS. THE GROUP ALSO PROVIDES BUSINESS PLANNING SUPPORT FOR MORE MATURE AMF PROGRAMS THAT ARE ON THEIR WAY TO BEING COMMERCIALIZED. AMF HAS SEVERAL EARLY STAGE RESEARCH AND DEVELOPMENT EFFORTS UNDER WAY IN THIS GROUP THAT ARE DIRECTED AT DEVELOPING ADVANCED TECHNOLOGIES AND CONCEPTS, INCLUDING INNOVATIVE USES FOR SENSORS TO PROVIDE FEEDBACK FOR RESPIRATORY PRODUCTS, NOVEL PACKAGING AND MANUFACTURING PROCESSES FOR IMPLANTABLE DEVICES INCLUDING SIMULATORS AND PUMPS. STATUS:AS THE PROJECTS ARE IN INITIAL FEASIBILITY OR PROOF-OF-CONCEPT STAGE FOR THE MOST PART, EXPENDITURES ON ANY INDIVIDUAL PROJECT ARE LIMITED. SUCCESSFUL PROJECTS ARE SCREENED FOR ELEVATION TO DEVELOPMENT PROGRAM STATUS, OR TO BE FINANCED IN SPINOUT COMPANIES BY THIRD PARTIES. UNSUCCESSFUL EFFORTS ARE TERMINATED. DURING THE PREVIOUS PERIOD, A NUMBER OF NEW INNOVATIVE PROJECTS HAVE BEEN EVALUATED BY THE TEAM. SEVERAL NEW AND PROMISING AREAS WERE EVALUATED AND ONE OR MORE WILL BECOME FORMAL PROJECTS IN 2017. 1357592 0 0 Sleep Apnea:AMF is investigating the need for newer methods to treat obstructed sleep apnea (OSA). OSA is a poorly treated medical condition where current treatment options are poorly adopted and when adopted, have significantly poor compliance rates.Status:A comprehensive healthcare economic analysis was performed this year demonstrating a need for a tolerable treatment. Several potential designs have been reviewed, which has included a number for bench, animal and cadevaour experiments. Further testing will be completed this calendar year, with a final design anticipated this calendar year. At this point formal product develop will begin. (Expenses: $1,040,735; Including grants of: $0; Revenues: $0)LEADED IMPLANTABLE MYOELECTRIC SENSOR (LIMES):AMF HAS RECEIVED FUNDING FROM DARPA TO DEVELOP A DERIVATIVE VERSION OF THE IMES DEVICE, BY ATTACHING A LEAD TO THE IMES CAPSULE. THE LEAD SIGNIFICANTLY EXTENDS THE BENEFITS OF IMES, PARTICULARLY WHEN THE TARGETED RESIDUAL MUSCLE IS OF INSUFFICIENT SIZE TO SUPPORT THE IMPLANTATION OF THE CAPSULE. THIS PROJECT WILL QUALIFY BIPOLAR LEAD ATTACHMENT PROCESSES AND SATISFY TECHNICAL REQUIREMENTS FOR INTENDED USE IN HUMANS. STATUS: THE PROJECT IS complete with all design documents completed and archived. (EXPENSES: $154,140; Including grants of: $0; Revenues: $0)Function Electrical Battery Powered Microstimulator (FEBPM):The FEBPM program (formerly the Battery Powered Microstimulator (BPM) program) is the development of the next-generation Microstimulator system. It is designed for a wide range of medical applications including localized individual muscle control and orchestrated muscle group control. The present Microstimulator is powered and controlled through an external RF field and only a few microstimulators can be controlled at once using a control algorithm installed on a PC and utilizing limited activity sequences. By contrast, the FEBPM implant has its own power supply which can be recharged as needed and then can operate for periods of time. Numerous FEBPM's can be communicated with and controlled using one external controller. Future versions of the FEBPM system may also contain sensors capable of communicating back to the controller to deliver various types of information used for system operation.Status:Based on other priorities within AMF, the FEBPM program was temporally slowed down while focus was placed on other programs. (Expenses: $59,537; Including grants of: $0; Revenues: $0)Neural Respiratory Drive (NRD):Neural respiratory drive (NRD) is an indicie derived from electromyography (EMG) signals measured from respiratory muscles. Successful early interventions with respect to respiratory conditions may mitigate or eliminate the need for hospitalization.Status:AMF is evaluating potential technical approaches to the problem. A clinical research system will be developed in calendar year 2016. (Expenses: $103,180; Including grants of: $0; Revenues: $0) 1357592 0 0 14589088 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 1 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 36 0 1 89 1 1 1 0 0 0 0 0 0 0 0 0 X 4 4 0 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 CA X petrina harris 6617026883 25134 RYE CANYON LOOP SANTA CLARITA CA 91355 ROBERT GREENBERG CHAIRMAN 2.00 X X 0 0 0 RICHARD WAUGH BOARD MEMBER 2.00 X 0 0 0 Mari DANIHEL bOARD MEMBER 2.00 X 0 0 0 BRIAN MANN BOARD MEMBER 0.50 X 0 0 0 DAVID HANKIN CEO 55.00 X 454114 0 33011 FARAH BOROOMAND cfo 52.00 X 269884 0 26583 MARK CHAMBERLAIN coo 56.00 X 327021 0 26726 JOHN PETROVICH GENERAL COUNSEL & SVP of Business Development 52.00 X 328724 0 20922 MICHAEL PERRIN VP, QUALITY Assurance & Regulatory affairs 50.00 X 187416 0 23627 Desmond B Keenan CTO 51.00 X 226688 0 11699 James H Wolfe PRINCIPAL ASIC DESIGN ENGIneer 40.00 X 186747 0 25394 GLEN GRIFFITH Technical director 42.00 X 225009 0 19630 Neelima Firth Sr. Director, Strategic planning & development 40.00 X 182648 0 15745 Edward Lee Senior ASIC Design Engineer 40.00 X 192174 0 20596 Siegmar Schmidt Emerging technologies group manager 42.00 X 179021 0 15359 2759446 0 239292 45 0 1 0 Morgan Lewis & Bockius LLP 300 S Grand Avenue 22nd Floor Los Angeles CA 90071 Legal Services 1619693 Modern Butler LLC dba majordomo 960 N alfred street 204 Los Angeles CA 90069 Event planning services 131974 2 1064153 60085 95452 1124238 research grant income 900099 926616 926616 926616 1984818 385640 1599178 23399 23399 113884766 6734 113002730 6447 882036 287 882323 882323 175000 1064153 582757 -407757 -407757 other income 999999 6898 6898 6898 4540535 950015 385640 2080642 7000 7000 1929622 1453283 476339 7443968 6644525 789282 10161 126978 114118 12714 146 757836 711141 45953 742 609108 523370 84961 777 1829060 1730097 98963 107870 107870 346652 346652 880005 748477 121417 10111 1119515 1014108 85150 20257 368882 319761 49121 999276 839066 140190 20020 125223 63984 61239 31068 20110 10958 322905 236190 86149 566 98753 82935 13838 1980 Miscellaneous 79551 33976 45575 Education & Morale 69938 46947 22108 883 17253210 14589088 2598479 65643 1963816 1430225 1334675 1335933 98181 78448 9688256 0 414872 323181 8690723 7216135 1573051 1474588 83205449 44957810 9402551 31674112 724245 736306 228444 102831 108633540 82113434 1902791 1777475 13316543 6379520 15219334 8156995 X 93414206 73956439 93414206 73956439 108633540 82113434 -12712675 -6745092 0 X 0 1 X 1 1 1 X WALTER REED NATIONAL MILITARY MEDICAL CENTER BETHESDA MD UCLA Foundation Department of Physiology Los Angeles CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1603585 601478 1002107 4806660 4393176 413484 2280478 2221481 58997 1474588 limited partnerships 1215856 F bioness inc. 2077000 F MEDALLION THERAPEUTICS, INC. 19905480 F MONOLYTHIX, inc. 2923416 F Axonics Modulation Technologies, Inc. 5552360 F 31674112 X Part X, Line 2: The Foundation, under the provisions of ASC 740, Income Taxes, had no uncertain tax positions requiring accrual as of March 31, 2016 and 2015. CENTRAL AMERICA AND THE CARIBBEAN 0 0 INVESTMENTS 7326470 cENTRAL AMERICA AND THE CARIBBEAN 0 0 INVESTMENT FEE EXPENDITURES 10981 0 0 0 0 0 0 7337451 0 7337451 1 0 1 1 1 0 Part I, line 3: THE ACCRUAL METHOD OF ACCOUNTING IS USED FOR BOTH AMOUNTS REPORTED AS INVESTMENTS AND EXPENDITURES. Concert 1239153 1064153 175000 582757 1239153 1064153 175000 582757 582757 -407757 X X X 1 0 0 0 0 0 0 1 0 DAVID HANKIN CEO 342114 0 100000 0 12000 0 5299 0 27712 0 487125 0 0 0 FARAH BOROOMAND cfo 219884 0 50000 0 0 0 4738 0 21845 0 296467 0 0 0 MARK CHAMBERLAIN coo 279521 0 47500 0 0 0 5299 0 21427 0 353747 0 0 0 JOHN PETROVICH GENERAL COUNSEL & SVP of Business De 258724 0 70000 0 0 0 5299 0 15623 0 349646 0 0 0 MICHAEL PERRIN VP, QUALITY Assurance & Regulatory a 162416 0 25000 0 0 0 3451 0 20176 0 211043 0 0 0 Desmond B Keenan CTO 211688 0 15000 0 0 0 3434 0 8265 0 238387 0 0 0 James H Wolfe PRINCIPAL ASIC DESIGN ENGIneer 185747 0 1000 0 0 0 3880 0 21514 0 212141 0 0 0 GLEN GRIFFITH Technical director 212509 0 12500 0 0 0 4448 0 15182 0 244639 0 0 0 Neelima Firth Sr. Director, Strategic planning & d 177648 0 5000 0 0 0 3048 0 12697 0 198393 0 0 0 Edward Lee Senior ASIC Design Engineer 192174 0 0 0 0 0 3768 0 16828 0 212770 0 0 0 Siegmar Schmidt Emerging technologies group manager 169021 0 10000 0 0 0 3598 0 11761 0 194380 0 0 0 Part I, Line 4a Neelima Firth - Received a severance payment in amount of $33,997.16 in return for signing a release agreement. Part I, Line 7 BONUS PAYMENTS WERE MADE, BUT ARE BASED ON ACHIEVEMENTS, GOALS, AND ARE APPROVED BY BOARD OF DIRECTORS. X 1 95452 fair market value 0 0 0 Form 990, Part VI, Section A, line 6 The foundation's articles of incorporation provide that the foundation is a membership corporation, with the members having the rights of membership as described in the foundation's bylaws. Form 990, Part VI, Section A, line 7a The foundation's articles of incorporation provide that the foundation shall have one lead member who has the power to appoint, remove and name successors to the members of the foundation's board of directors. Form 990, Part VI, Section B, line 11 A DRAFT OF FORM 990 WAS PRESENTED BY MANAGEMENT TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR THEIR REVIEW AND DISCUSSION. A FULL COPY OF THE FORM WAS PROVIDED TO ALL VOTING MEMBERS PRIOR TO FILING WITH THE IRS. Form 990, Part VI, Section B, line 12c CONFLICT OF INTEREST DISCLOSURES ARE UPDATED ANNUALLY AND POTENTIAL CONFLICTS ARE REVIEWED PRIOR TO PARTICIPATING IN TRANSACTIONS. IF A CONFLICT EXISTS, THE PERSON WITH A CONFLICT DOES NOT VOTE. THErE HAVE BEEN NO INCIDENCES THIS REPORTING YEAR. Form 990, Part VI, Section B, line 15 THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE COMPENSATION OF THE CEO AND HIS DIRECT REPORTS INCLUDING THE CFO. THEY ALSO REVIEW AND APPROVE THE OVERALL ANNUAL ADJUSTMENTS TO COMPENSATION OF OTHER EMPLOYEES. SPECIFIC ADJUSTMENTS FOR OTHER EMPLOYEES ARE HANDLED BY THE CEO AND HEAD OF HUMAN RESOURCES USING COMPARISONS TO SALARY SURVEYS FOR SIMILAR POSITIONS AND EXPERIENCE. DURING THE YEAR ENDED MARCH 31, 2015, THE foundation HAD AN OUTSIDE COMPENSATION ANALYSIS COMPLETED COVERING EXECUTIVE MANAGEMENT, KEY EMPLOYEES AND HIGHLY COMPENSATED EMPLOYEES. THE BOARD OF DIRECTORS APPROVED COMPENSATION FOR THE CEO AND HIS DIRECT REPORTS INCLUDING THE CFO. THIS PROCESS WAS DOCUMENTED. Form 990, Part VI, Section C, line 19 MEMBERS OF THE PUBLIC OR INTERESTED PARTIES MAY REQUEST TO REVIEW OR RECIEVE A COPY OF THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS BY PHONE OR MAIL. core manufacturing llc 26432 oakdale canyon lane canyon country CA 91387 manufacturing & Research CA N/A unrelated 0 0 BIONESS INC 25103 rye canyon loop valencia CA 91355 design manufacture & sale of medical devices DE N/A C 0.02810 0 Axonics Modulation Technologies Inc 7575 irvine center drive suite 200 Irvine CA 92618 454744083 Development and commercialization of medical device (sacral neuromodulation) DE N/A C 0.18780 0 Monolythix Inc 4720 calle carga camarillo CA 93012 464616473 Monolithic structure development for disease detection, blood analysis NV ALFRED E MANN FOUNDATION FOR SCIENTIFIC RESEARCH C 637125 0.69650 1 Medallion Therapeutics Inc 28575 livingston avenue Valencia CA 91355 464651082 Development and commercialization of medical device (implantable drug pump) DE ALFRED E MANN FOUNDATION FOR SCIENTIFIC RESEARCH C -5995440 6272686 0.96330 1 1 0 0 1 0 0 1 0 0 1 0 0 0 1 1 0 1 0 0 medallion therapeutics inc D 6374559 Loan MOnolythix inc A 111081 INTEREST INCOME MEdallion therapeutics inc A 274559 INTEREST INCOME MONOlythix inc D 311081 Loan